Taken together, this shows galR1 may be preferentially upregulated in some cancer types to benefit from its antiapoptotic effects on caspase activation, and addition of galR1 antagonists may prove beneficial as adjunctive therapy. The gene discussed is GALR1; the disease is cancer.